Literature DB >> 29048187

Electronic cigarette user plasma nicotine concentration, puff topography, heart rate, and subjective effects: Influence of liquid nicotine concentration and user experience.

Marzena Hiler1, Alison Breland1, Tory Spindle1, Sarah Maloney1, Thokozeni Lipato1, Nareg Karaoghlanian2, Alan Shihadeh1, Alexa Lopez1, Carolina Ramôa1, Thomas Eissenberg1.   

Abstract

Electronic cigarette (ECIG) nicotine delivery and other effects may depend on liquid nicotine concentration and user experience. This study is the first to systematically examine the influence of ECIG liquid nicotine concentration and user experience on nicotine delivery, heart rate, puff topography, and subjective effects. Thirty-three ECIG-experienced individuals and 31 ECIG-naïve cigarette smokers completed 4 laboratory conditions consisting of 2, 10-puff bouts (30-sec interpuff interval) with a 3.3-V ECIG battery attached to a 1.5-Ω "cartomizer" (7.3 W) filled with 1 ml ECIG liquid. Conditions differed by liquid nicotine concentration: 0, 8, 18, or 36 mg/ml. Participants' plasma nicotine concentration was directly related to liquid nicotine concentration and dependent on user experience, with significantly higher mean plasma nicotine increases observed in ECIG-experienced individuals relative to ECIG-naïve smokers in each active nicotine condition. When using 36 mg/ml, mean plasma nicotine increase for ECIG-experienced individuals was 17.9 ng/ml (SD = 17.2) and 6.9 (SD = 7.1; p < .05) for ECIG-naïve individuals. Between-group differences were likely due to longer puffs taken by experienced ECIG users: collapsed across condition, mean puff duration was 5.6 sec (SD = 3.0) for ECIG-experienced and 2.9 (SD = 1.5) for ECIG-naïve individuals. ECIG use also suppressed nicotine/tobacco abstinence symptoms in both groups; the magnitude of abstinence symptom suppression depended on liquid nicotine concentration and user experience. These and other recent results suggest that policies intended to limit ECIG nicotine delivery will need to account for factors in addition to liquid nicotine concentration (e.g., device power and user behavior). (PsycINFO Database Record (c) 2017 APA, all rights reserved).

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29048187      PMCID: PMC5657238          DOI: 10.1037/pha0000140

Source DB:  PubMed          Journal:  Exp Clin Psychopharmacol        ISSN: 1064-1297            Impact factor:   3.157


  42 in total

1.  Evaluation of the brief questionnaire of smoking urges (QSU-brief) in laboratory and clinical settings.

Authors:  L S Cox; S T Tiffany; A G Christen
Journal:  Nicotine Tob Res       Date:  2001-02       Impact factor: 4.244

Review 2.  Measuring the emergence of tobacco dependence: the contribution of negative reinforcement models.

Authors:  Thomas Eissenberg
Journal:  Addiction       Date:  2004-06       Impact factor: 6.526

3.  Effects of using electronic cigarettes on nicotine delivery and cardiovascular function in comparison with regular cigarettes.

Authors:  X Sherwin Yan; Carl D'Ruiz
Journal:  Regul Toxicol Pharmacol       Date:  2014-11-22       Impact factor: 3.271

4.  Electronic cigarette effectiveness and abuse liability: predicting and regulating nicotine flux.

Authors:  Alan Shihadeh; Thomas Eissenberg
Journal:  Nicotine Tob Res       Date:  2014-09-01       Impact factor: 4.244

5.  Effects of Electronic Cigarette Liquid Nicotine Concentration on Plasma Nicotine and Puff Topography in Tobacco Cigarette Smokers: A Preliminary Report.

Authors:  Alexa A Lopez; Marzena M Hiler; Eric K Soule; Carolina P Ramôa; Nareg V Karaoghlanian; Thokozeni Lipato; Alison B Breland; Alan L Shihadeh; Thomas Eissenberg
Journal:  Nicotine Tob Res       Date:  2015-09-16       Impact factor: 4.244

6.  Optimal carbon monoxide criteria to confirm 24-hr smoking abstinence.

Authors:  Kenneth A Perkins; Joshua L Karelitz; Nancy C Jao
Journal:  Nicotine Tob Res       Date:  2012-09-18       Impact factor: 4.244

7.  Electronic cigarette nicotine delivery can exceed that of combustible cigarettes: a preliminary report.

Authors:  Carolina P Ramôa; Marzena M Hiler; Tory R Spindle; Alexa A Lopez; Nareg Karaoghlanian; Thokozeni Lipato; Alison B Breland; Alan Shihadeh; Thomas Eissenberg
Journal:  Tob Control       Date:  2015-08-31       Impact factor: 7.552

8.  Transdermal nicotine: reduction of smoking with minimal abuse liability.

Authors:  W B Pickworth; E B Bunker; J E Henningfield
Journal:  Psychopharmacology (Berl)       Date:  1994-06       Impact factor: 4.530

9.  Nicotine absorption from electronic cigarette use: comparison between experienced consumers (vapers) and naïve users (smokers).

Authors:  Konstantinos E Farsalinos; Alketa Spyrou; Christos Stefopoulos; Kalliroi Tsimopoulou; Panagiota Kourkoveli; Dimitris Tsiapras; Stamatis Kyrzopoulos; Konstantinos Poulas; Vassilis Voudris
Journal:  Sci Rep       Date:  2015-06-17       Impact factor: 4.379

10.  The Influence of a Mouthpiece-Based Topography Measurement Device on Electronic Cigarette User's Plasma Nicotine Concentration, Heart Rate, and Subjective Effects Under Directed and Ad Libitum Use Conditions.

Authors:  Tory R Spindle; Marzena M Hiler; Alison B Breland; Nareg V Karaoghlanian; Alan L Shihadeh; Thomas Eissenberg
Journal:  Nicotine Tob Res       Date:  2017-04-01       Impact factor: 4.244

View more
  53 in total

Review 1.  Recent findings in the pharmacology of inhaled nicotine: Preclinical and clinical in vivo studies.

Authors:  Asti Jackson; Ben Grobman; Suchitra Krishnan-Sarin
Journal:  Neuropharmacology       Date:  2020-06-24       Impact factor: 5.250

Review 2.  Electronic nicotine delivery systems and pregnancy: Recent research on perceptions, cessation, and toxicant delivery.

Authors:  Alison Breland; Andrea McCubbin; Kristin Ashford
Journal:  Birth Defects Res       Date:  2019-07-31       Impact factor: 2.344

3.  Limited utility of detailed e-cigarette use measures: An analysis of NESARC-III.

Authors:  Maria A Parker; Jennifer L Pearson; Andrea C Villanti
Journal:  Addict Behav       Date:  2019-05-02       Impact factor: 3.913

4.  Answering questions about electronic cigarettes using a multidisciplinary model.

Authors:  Alison Breland; Robert L Balster; Caroline Cobb; Pebbles Fagan; Jonathan Foulds; J Randy Koch; Thokozeni Lipato; Najat Saliba; Alan Shihadeh; Shumei Sun; Thomas Eissenberg
Journal:  Am Psychol       Date:  2019-04

5.  Acceptability of electronic nicotine delivery systems (ENDS) among HIV positive smokers.

Authors:  Jessica Yingst; Jonathan Foulds; John Zurlo; Michael B Steinberg; Thomas Eissenberg; Ping Du
Journal:  AIDS Care       Date:  2019-11-07

6.  Assessing electronic cigarette effects and regulatory impact: Challenges with user self-reported device power.

Authors:  Alyssa K Rudy; Adam M Leventhal; Nicholas I Goldenson; Thomas Eissenberg
Journal:  Drug Alcohol Depend       Date:  2017-08-18       Impact factor: 4.492

7.  E-cigarette nicotine dose and flavor: Relationship with appeal, choice, and tobacco use amongst veterans with comorbid psychiatric disorders.

Authors:  Elise E DeVito; Eugenia Buta; Mehmet Sofuoglu
Journal:  Addict Behav       Date:  2018-12-17       Impact factor: 3.913

8.  "I cannot live without my vape": Electronic cigarette user-identified indicators of vaping dependence.

Authors:  Eric K Soule; Joseph G L Lee; Kathleen L Egan; Kendall M Bode; Abigail C Desrosiers; Mignonne C Guy; Alison Breland; Pebbles Fagan
Journal:  Drug Alcohol Depend       Date:  2020-02-05       Impact factor: 4.492

9.  Vaping characteristics and expectancies are associated with smoking cessation propensity among dual users of combustible and electronic cigarettes.

Authors:  Karen O Brandon; Vani N Simmons; Lauren R Meltzer; David J Drobes; Úrsula Martínez; Steven K Sutton; Amanda M Palmer; Christopher R Bullen; Paul T Harrell; Thomas H Brandon
Journal:  Addiction       Date:  2019-02-13       Impact factor: 6.526

10.  Electronic Nicotine Delivery System Aerosol-induced Cell Death and Dysfunction in Macrophages and Lung Epithelial Cells.

Authors:  Gregory L Serpa; Nicholas D Renton; Nari Lee; Meredith J Crane; Amanda M Jamieson
Journal:  Am J Respir Cell Mol Biol       Date:  2020-09       Impact factor: 6.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.